Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 6, 2016, Pages 717-724

  Monteleone, G ^a   Di Sabatino, A ^b   Ardizzone, S ^c   Pallone, F ^a   Usiskin, K ^d   Zhan, X ^d   Rossiter, G ^d   Neurath, M F ^e  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d CELGENE CORPORATION   (United States)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; C REACTIVE PROTEIN; CORTICOSTEROID; MONGERSEN; PLACEBO; SMAD7 PROTEIN; OLIGONUCLEOTIDE;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; C-REACTIVE PROTEIN; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; REMISSION INDUCTION; SMAD7 PROTEIN; TREATMENT OUTCOME;

EID: 84958680040     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13526     Document Type: Article

References (17)

1. Randall CW, Vizuete JA, Martinez N, et al,. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol 2015; 8: 143-59.
2. Boyapati R, Satsangi J, Ho GT,. Pathogenesis of Crohn's disease. F1000Prime Rep 2015; 7: 44.
3. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT,. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108: 601-9.
4. Monteleone G, Fantini MC, Onali S, et al,. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther 2012; 20: 870-6.
5. Zorzi F, Calabrese E, Monteleone I, et al,. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol Ther 2012; 36: 850-7.
6. Monteleone G, Neurath MF, Ardizzone S, et al,. Mongersen, an oral Smad7 antisense oligonucleotide, and Crohn's disease. N Engl J Med 2015; 372: 1104-13.
7. Parsi MA, Achkar JP, Richardson S, et al,. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 707-13.
8. Reinisch W, Wang Y, Oddens BJ, Link R,. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012; 35: 568-76.
9. Arnott ID, McNeill G, Satsangi J,. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1451-7.
10. Vermeire S, Louis E, Carbonez A, et al,. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 2357-63.
11. Schreiber S, Reinisch W, Colombel JF, et al,. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2013; 7: 213-21.
12. Sandborn WJ, Colombel JF, Panes J, et al,. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials. J Crohns Colitis 2013; 7: 958-67.
13. Sandborn WJ, Colombel JF, D'Haens G, et al,. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-13.
14. Schreiber S, Colombel JF, Bloomfield R, et al,. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010; 105: 1574-82.
15. Van Assche G, Dignass A, Panes J, et al,. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.
16. D'Haens G, Baert F, Van Assche G, et al,. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7.
17. Feagan BG, Sandborn WJ, Wolf DC, et al,. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011; 33: 541-50.